Sanofi has completed its acquisition of Dynavax Technologies Corporation, adding the hepatitis B vaccine HEPLISAV-B and a pipeline of vaccine assets to its portfolio. The deal also includes a shingles vaccine candidate (Z-1018) currently in Phase 1/2 studies, along with additional vaccine pipeline assets.
The tender offer expired on February 9, 2026, with all conditions satisfied. Non-tendered shareholders received $15.50 per share in cash through a subsequent Delaware merger that made Dynavax an indirect Sanofi subsidiary. Dynavax ceased trading on NASDAQ as of February 10, 2026.
Sanofi characterized the acquisition as a strategic move to expand its adult immunization presence by combining Dynavax’s vaccines, including HEPLISAV-B’s distinctive two-dose regimen administered over one month, with Sanofi’s commercial infrastructure and development capabilities.